Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)
Sponsor: University Hospital, Bordeaux
Summary
Myelodysplastic syndromes (MDS) are clonal diseases of hematopoietic stem cells (HSC) characterized by dysplastic and inefficient hematopoiesis related to excessive progenitor cell death. Ferroptosis is a recently described cell death mechanism and we think that it could be a major player in the pathophysiology of MDS, involved in the cell death that characterizes these diseases and contributing to cytopenias. The study aims to demonstrate that there is a significant activation of this phenomenon in MDS patients compared to a population of subjects without MDS.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-02-21
Completion Date
2027-02
Last Updated
2025-03-19
Healthy Volunteers
No
Conditions
Interventions
Biological sampling
The procedure will consist of an additional bone marrow sample and blood sample
Locations (3)
CHU de Bordeaux, Laboratoire d'Hématologie
Pessac, France
CHU de Bordeaux, Service de Médecine Interne
Pessac, France
CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire
Pessac, France